The American Society of Transplant Surgeons (ASTS) champions efforts to increase organ donation. Controlled donation after cardiac death (DCD) offers the family and the patient with a hopeless prognosis the option to donate when brain death criteria will not be met. Although DCD is increasing, this endeavor is still in the midst of development. DCD protocols, recovery techniques and organ acceptance criteria vary among organ procurement organizations and transplant centers. Growing enthusiasm for DCD has been tempered by the decreased yield of transplantable organs and less favorable posttransplant outcomes compared with donation after brain death. Logistics and ethics relevant to DCD engender discussion and debate among lay and medical communities. Regulatory oversight of the mandate to increase DCD and a recent lawsuit involving professional behavior during an attempted DCD have fueled scrutiny of this activity. Within this setting, the ASTS Council sought best-practice guidelines for controlled DCD organ donation and transplantation. The proposed guidelines are evidence based when possible. They cover many aspects of DCD kidney, liver and pancreas transplantation, including donor characteristics, consent, withdrawal of ventilatory support, operative technique, ischemia times, machine perfusion, recipient considerations and biliary issues. DCD organ transplantation involves unique challenges that these recommendations seek to address.
Introduction

The American Society of Transplant Surgeons (ASTS) champions efforts to increase the number of organs that are available for critically needed transplants. One important effort involves transplantation of donation after cardiac death (DCD) organs and improving outcomes of these transplants. This goal is particularly relevant because DCD donors have been shown to be a potential source of transplantable organs that has yet to be fully utilized (1,2). Cardiac death is defined as 'irreversible cessation of circulatory and respiratory function' (1-5). Controlled DCD involves planned withdrawal of ventilatory and organ-perfusion support in the face of catastrophic illness (Maastricht III), whereas uncontrolled DCD involves unexpected cardiopulmonary arrest and/or unsuccessful resuscitation (Maastricht I, II, IV) (1-6). Controlled DCD offers the patient and the family the opportunity to donate when criteria for brain death declaration will not have been met prior to cardiac death. It should be emphasized that whether or not organ donation is to be pursued, such patients' legal decision maker(s) elect to withdraw ventilatory support because of a hopeless prognosis. The transplant community has no say in whether or when support will be withdrawn. Furthermore, it must be recognized that the patient who is considered for DCD is not dead and not a donor unless
and until he or she should die.
Growing enthusiasm about the option of DCD organ procurement ought to be tempered by the realization that both
Donation after Cardiac Death: Best Practices the yield of transplantable organs from DCDs and the outcomes after DCD organ transplantation are not generally as favorable as those with donation after brain death (DBD)
organs (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) . DCD shall not be viewed as an equally acceptable alternative to DBD because DCD on average yields fewer organs and the organs probably have more risk than organs recovered from DBD donors (7) (8) (9) (10) (11) (12) (14) (15) (16) (17) (18) (19) (1) (2) (3) (23) (24) (25) (26) (27) 
Withdrawal of ventilatory and organ-perfusion support
• Optimally, withdrawal of ventilatory and organperfusion support will occur in the operating room.
However, it is recognized that this is not always possible and that OPO efforts to facilitate the potential DCD donor's family wishes shall be supported. • The family can be given the opportunity to spend time with the patient immediately prior to and during discontinuation of support and until cessation of cardiorespiratory function. • Heparin shall be administered, prior to withdrawal of support, except in the rare case when it might be expected to hasten death and/or is prohibited per local procurement protocol (3,23,24,26). Phentolamine may be administered per local procurement protocol as long as it is not expected to hasten death. Specific informed consent for administration of each of these agents shall be obtained from the patient's legal decision maker(s) prior to withdrawal of support (3,23,24,26). • Morphine and/or other analgesics may be given at the discretion of the patient's treating care team if the purpose is to minimize discomfort in a dying patient according to accepted end-of-life protocols, even if this might hasten death as an unintended consequence. Procurement team members shall not participate in decisions regarding the use of such agents (3,23,24,26). • Members of the procurement team may be present prior to withdrawal of ventilatory and organ-perfusion support to prepare and drape the patient. During such preparation and draping, it is critical to recognize that the potential DCD donor is a patient who is still alive. • Members of the procurement team shall not be in the presence of the patient at the time of withdrawal of support and until the declaration of death (this includes absence during withdrawal of ventilatory and organperfusion support, until the time of cardiorespiratory arrest, and through the waiting period until declaration of death-see below) (23,26). • The patient's treating care team stops ventilation.
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• (33, 34) . Specific informed consent shall be obtained if this technique is to be used (1) (2) (3) 23, 24, 26 
Ischemia times
• Efforts shall be made to minimize both warm and cold ischemia times during DCD organ procurement and transplantation (11, 13, 14, 19, 24, 33 (11, 13, 14, 24, 33) . * Cold ischemia time longer than 8-10 h (10, 11, 24 (3, 24, 39, 40) .
Biliary issues
• DCD liver transplantation has been associated with the development of ischemic biliary complications (11, (14) (15) (16) (11, 13, 14, (41) (42) (43) . * Consider arterial revascularization before or simultaneously with portal revascularization of DCD livers (14, 43 
